Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

18.9K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
18.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same author

A comprehensive LC-MS based study of factors influencing biotinylation of critical reagents.

Bioanalysis·2024
Same author

2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody <u>(PART 1A</u> - Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis <u>PART 1B</u> - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine).

Bioanalysis·2024
Same author

2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (<u>Part 1A</u> - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization <u>Part 1B</u> - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine).

Bioanalysis·2023
Same author

Contribution of UGT Enzymes to Human Drug Metabolism Stereoselectivity: A Case Study of Medetomidine, RO5263397, Propranolol, and Testosterone.

Drug metabolism and disposition: the biological fate of chemicals·2023
Same author

Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity.

Immunology·2022

Related Experiment Video

Updated: Apr 10, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

868

An Innovative Multifaceted Approach to Enhance the Sensitivity of a Target Engagement ELISA.

Nahong Qiu1, Alexandra Nitsche1, Isabelle Beley1

  • 1PK Sciences, Translational Medicine, Biomedical Research, Novartis AG, WSJ-350, Basel, CH-4056, Switzerland.

Pharmaceutical Research
|April 8, 2026
PubMed
Summary

This study introduces a novel enzyme-linked immunosorbent assay (ELISA) method to significantly boost sensitivity for measuring low-level protein targets. The enhanced assay achieves a 200-fold increase in sensitivity, crucial for accurate target engagement assessments.

Keywords:
ELISAIMAplate™Pluronic® F-127bioanalytical challengeenhance sensitivitytarget engagement

More Related Videos

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.4K
Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

44.4K

Related Experiment Videos

Last Updated: Apr 10, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

868
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.4K
Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

44.4K

Area of Science:

  • Bioanalytical Chemistry
  • Immunotechnology
  • Assay Development

Background:

  • Target engagement (TE) assessments face bioanalytical challenges with low-abundance targets like cytokines.
  • Commercial immunoassays often lack the required sensitivity and are prone to drug interference.
  • Accurate quantification of low-concentration analytes is critical for drug development and efficacy studies.

Purpose of the Study:

  • To develop a highly sensitive sandwich ELISA methodology for TE assessment.
  • To overcome limitations of conventional ELISAs in detecting low-level analytes.
  • To improve the limit of quantification for challenging biomarkers such as interleukin-13 (IL-13).

Main Methods:

  • Combined U-bottomed plates and Intelligent Multifunctional Analytical Plates (IMAPlate™) for signal concentration.
  • Incorporated Pluronic® F-127 detergent to reduce background noise.
  • Optimized biotinylation and utilized poly-horseradish peroxidase (HRP)-streptavidin for signal amplification.
  • Implemented a saturation method to address steric hindrance with anti-IL-13 monoclonal antibody (mAb).

Main Results:

  • Achieved a 200-fold enhancement in assay sensitivity.
  • Established a limit of quantification of 0.05 pg/mL for human IL-13.
  • Successfully mitigated drug interference and steric hindrance issues.
  • Demonstrated broad applicability in other sensitive ELISA-based bioanalytical assays.

Conclusions:

  • The novel ELISA methodology significantly enhances sensitivity for low-level protein quantification.
  • This approach overcomes key bioanalytical challenges in TE assessments.
  • The developed method offers a robust and versatile tool for sensitive biomarker detection.